GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (FRA:PCJ) » Definitions » Cyclically Adjusted PS Ratio

Abeona Therapeutics (FRA:PCJ) Cyclically Adjusted PS Ratio : (As of May. 26, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Abeona Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Abeona Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Cyclically Adjusted PS Ratio Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.62 0.15 0.14 -

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.47 - - -

Competitive Comparison of Abeona Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Abeona Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Cyclically Adjusted PS Ratio falls into.



Abeona Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Abeona Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Abeona Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0/131.7762*131.7762
=0.000

Current CPI (Mar. 2024) = 131.7762.

Abeona Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 8.667 100.560 11.357
201409 8.714 100.428 11.434
201412 0.238 99.070 0.317
201503 0.298 99.621 0.394
201506 0.244 100.684 0.319
201509 0.200 100.392 0.263
201512 0.150 99.792 0.198
201603 0.161 100.470 0.211
201606 0.145 101.688 0.188
201609 0.123 101.861 0.159
201612 0.160 101.863 0.207
201703 0.108 102.862 0.138
201706 0.120 103.349 0.153
201709 0.114 104.136 0.144
201712 0.100 104.011 0.127
201803 0.229 105.290 0.287
201806 0.125 106.317 0.155
201809 0.766 106.507 0.948
201812 0.221 105.998 0.275
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 1.602 109.815 1.922
202012 0.664 109.897 0.796
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.000 115.734 0.000
202112 0.634 117.630 0.710
202203 0.054 121.301 0.059
202206 0.163 125.017 0.172
202209 0.000 125.227 0.000
202212 0.004 125.222 0.004
202303 0.000 127.348 0.000
202306 0.179 128.729 0.183
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Abeona Therapeutics  (FRA:PCJ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Abeona Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (FRA:PCJ) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.

Abeona Therapeutics (FRA:PCJ) Headlines

No Headlines